Senseonics Archives - Page 5 of 6 - Medical Design Sourcing

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

MedTech 100 roundup: Industry sees largest fall since October

The medtech industry’s hot start to 2021 has finally come to a full halt after stocks fell harder than they had in more than four months.

MassDevice‘s MedTech 100 index ended the week (March 5) at 103.3 points, marking a -3.1% dip from the 106.65-point mark set one week before (Feb. 26). In less than a month, the fall has been more than seven points from the end-of-week tally of 110.63 points on Feb. 12.

Medtech’s lowest point of the week was on Thursday, March 4, when it fell to 102.85. The overall drop of about five points from the 107.88-point mark set on Monday, March 1, is the largest dip since the index slid from 97.2 to 91.01 between Oct. 23, 2020, and Oct. 30, 2020.

The all-time best for the index was 110.96, set just three days after that. The index had never reached even the 100-point mark before November 2020.

Still, the industry is in much better condition than it was around this time last year. Medtech’s latest mark means …

Senseonics sinks on mixed bag Q4, massive bottom-line slide

Senseonics (NYSE:SENS) shares took a hit today on fourth-quarter losses that missed the consensus earnings forecast.

SENS shares were hit hard at market close yesterday after financial results were released, dipping -15.7% to $2.69 per share. In pre-market trading this morning, they are down -7.8% at $2.48 per share.

The Germantown, Md.-based implantable continuous glucose monitor maker posted losses of -$101.6 million, or -41¢ per share, on sales of $3.9 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of -$35.6 million this time a year ago on a sales decline of -56.7%.

Get the full story at our sister site, Drug Delivery Business News.

Looking back at two decades of CGM advances

The Freestyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.-based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer (ETR:BAYN). The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

Get the full story on our sister site, Drug Delivery Business News.

Looking back at two decades of CGM advances

FreeStyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.-based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer (ETR: BAYN). The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to measure reflected light from a Dextrostix strip. It was the first blood glucose mete…

EmblemHealth to provide coverage for Senseonics’ Eversense CGM

Senseonics (NYSE:SENS) announced that EmblemHealth is now providing coverage for its Eversense continuous glucose monitoring system.

Germantown, Md.-based Senseonics said in a news release that the immediately effective decision adds to the number of payers writing the Eversense system into their CGM coverage policies and paying for the healthcare provider’s time for the in-office sensor placement.

Get the full story at our sister site, Drug Delivery Business News.

EmblemHealth to provide coverage for Senseonics’ Eversense CGM

Senseonics (NYSE:SENS) announced that EmblemHealth is now providing coverage for its Eversense continuous glucose monitoring system.

Germantown, Md.-based Senseonics said in a news release that the immediately effective decision adds to the number of payers writing the Eversense system into their CGM coverage policies and paying for the healthcare provider’s time for the in-office sensor placement.

EmblemHealth, which operates in New York, New Jersey and Connecticut, expands access to approximately 2.9 million residents across the three states with the addition of Eversense to its 2021 CGM policy.

Eversense features a fluorescence-based upper-arm sensor, a smart transmitter worn over the sensor and a mobile app for displaying glucose values, trends and alerts. The system also includes a smart transmitter that provides discreet on-body vibratory alerts and can be removed, recharged and re-attached without discarding the sensor.

“We are excite…

Senseonics announces $50M from stock offering

Senseonics (NYSE:SENS) announced that it entered into securities purchase agreements worth gross proceeds of approximately $50 million.

Germantown, Md.-based Senseonics’ purchase agreements are with several healthcare-focused investors, as well as other institutional investors, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Senseonics announces $50M from stock offering

Senseonics (NYSE:SENS) announced that it entered into securities purchase agreements worth gross proceeds of approximately $50 million.

Germantown, Md.-based Senseonics’ purchase agreements are with several healthcare-focused investors, as well as other institutional investors, according to a news release.

Investors have agreed to purchase 40 million shares of the implantable continuous glucose monitor maker’s common stock at a price of $1.25 per share, with the proceeds totaling $50 million, although Senseonics expects to collect about $46 million after deducting fees and commissions.

Senseonics said it intends to sue the net proceeds for general corporate purposes after the offering closes on or about Jan. 21, 2021 as the company expects. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

MedTech 100 roundup: Up-and-down week for industry

Medtech stocks highlighted the topsy-turvy nature of the market last week, but ultimately finished the seven days nearly unchanged.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.77 points at the end of last week (Aug. 14). Overall, medtech stocks saw a 0.13% increase from the 89.65-point total at the same time a week prior (Aug. 7).

On Aug. 13, the index reached 90.4 points, a total that nearly poked past the previous mid-pandemic high (90.45), which came just last week.

The most recent high mark represents just a -2.1% dip from the Feb. 19 high point of 92.32, while the tally at the end of the week marks a -2.8% decrease from that pre-pandemic high.

Meanwhile, the S&P 500 Index saw a 0.64% increase from Aug. 7 to Aug. 14, and the Dow Jones Index fared even better, rising 1.8% over the same period of time.

Medtech’s lowest point during the COVID-19 pandemic remains at …

Senseonics posts mixed bag Q2, partners with Ascensia

Senseonics (NYSE:SENS) shares rose slightly today on second-quarter results that were mixed compared to the consensus forecast.

The Germantown, Md.-based implantable continuous glucose monitor maker also announced a deal with Ascensia Diabetes Care for global commercialization and distribution with concurrent financing worth up to $50 million.

Senseonics posted losses of -$7.5 million, or -3¢ per share, on sales of $261,000 for the three months ended June 30, 2020, for a -75.8% bottom-line slide on a sales decline of -94.3%.

Adjusted to exclude one-time items, earnings per share were breakeven at zero, 9¢ ahead of Wall Street, where analysts were looking for sales of $1.43 million.

“Our second quarter results demonstrate significant expense and cash burn reductions resulting from our suspended commercial operations and other cost reduction initiatives,” Senseonics president & CEO Tim Goodnow said in a news release. “Anticipated rev…